Tumour targeting of lipid nanocapsules grafted with cRGD peptides. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles International Journal of Pharmaceutics Year : 2014

Tumour targeting of lipid nanocapsules grafted with cRGD peptides.


Combining targeting to therapy remains a major challenge in cancer treatment. To address this subject, the surface of lipid nanocapsules (LNC) was modified by grafting cRGD peptides, which are known to be recognised by αvβ3 integrins expressed by tumour endothelium and cancer cells. Applicability of this LNC-cRGD in tumour targeting was first assessed in vitro by the use of U87MG glioma cells. Biodistribution and tumour accumulation of radiolabelled LNC-cRGD in vivo were then evaluated in mice bearing the same subcutaneous xenograft. Flow cytometry and confocal microscopy results revealed that the cRGD grafting improved binding and internalisation compared to negative control LNC-cRAD and blank LNC. The peptide-grafted LNC remained in the blood circulation up to 3h with reduced capture by the RES organs. Tumour accumulation of LNC-cRGD with respect to LNC-cRAD was significantly higher at 1-3h. These results show that cRGD grafted to LNC has created a promising tumour-targetable nanocarrier that could be used in cancer treatment.
Fichier principal
Vignette du fichier
Hirsjarvi_2014_archives_ouvertes.pdf (300.19 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00923988 , version 1 (06-01-2014)



Samuli Hirsjärvi, Camille Belloche, François Hindré, Emmanuel Garcion, Jean-Pierre Benoit. Tumour targeting of lipid nanocapsules grafted with cRGD peptides.. International Journal of Pharmaceutics, 2014, 87 (1), pp.152-9. ⟨10.1016/j.ejpb.2013.12.006⟩. ⟨inserm-00923988⟩
484 View
506 Download



Gmail Facebook X LinkedIn More